Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | TYMS | P04818 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17117812 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL18785118 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL16678590 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL1971161 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL48232 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL25171429 | 0.99 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| Water SCHEMBL7247857 | 0.98 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL29258727 | 0.95 | POLB (0.77) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL30927571 | 0.95 | POLB (0.77) | POLBP2RY2P2RY4P2RY6NT5E | |
| Triphosphate SCHEMBL27909453 | 0.95 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3229610-B1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10457700-B2 | Platinum prodrugs and methods of making and using thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190021380-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180255813-A1 | METHODS FOR MODULATING TASTE RECEPTORS | MARS, INCORPORATED (US) | 2018-09-13 | — | — | US | disclosed |
| EP-2310534-B1 | BASE-DETECTING PORE | OXFORD NANOPORE TECH LTD (GB) | 2018-09-05 | — | — | EP | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180044362-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| US-9447152-B2 | Base-detecting pore | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| WO-2016144889-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2015089389-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150152476-A1 | REAGENTS AND METHODS FOR DIRECT LABELING OF NUCLEOTIDES | MARKER GENE TECHNOLOGIES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8916346-B2 | Reagents and methods for direct labeling of nucleotides | Marker Gene Technology, Inc. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130243769-A1 | INDUCED INTERNALIZATION OF SURFACE RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130150254-A1 | Reagents and methods for direct labeling of nucleotides | MARKER GENE TECHNOLOGIES, INC. | 2013-06-13 | — | — | US | disclosed |
| US-8420620-B2 | Induced internalization of surface receptors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110177498-A1 | BASE-DETECTING PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20100297124-A1 | INDUCED INTERNALIZATION OF SURFACE RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150254-A1 | Reagents and methods for direct labeling of nucleotides | DUT, DNTT, NUDT1 | POLB 27/4885P2RY2 246/4885P2RY4 110/4885 |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | POLB 1241/4885P2RY2 244/4885P2RY4 69/4885 |
| US-10457700-B2 | Platinum prodrugs and methods of making and using thereof | MGMT, DPYD, OGG1 | POLB 185/4885P2RY2 1990/4885P2RY4 1705/4885 |
| US-20180044362-A1 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | MGMT, DPYD, OGG1 | POLB 185/4885P2RY2 1990/4885P2RY4 1705/4885 |
| US-20150152476-A1 | REAGENTS AND METHODS FOR DIRECT LABELING OF NUCLEOTIDES | DUT, DNTT, NUDT1 | POLB 27/4885P2RY2 246/4885P2RY4 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.